Launching a new, undifferentiated drug in a mature and highly regulated market can be challenging—even for an established organization. Facing the loss of exclusivity for a blockbuster drug, a leading North American pharmaceutical company developed a new indication to maintain its competitiveness within the therapeutic area. With a handful of mature products already in the market, the company engaged Clarkston Consulting to develop an innovative strategy to optimize their new product launch.

To read more about the case study Maximizing an Undifferentiated Product Launch in a Mature Market click through on the link to the PDF below.